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Abstract Precision medicine is an emerging approach for
disease treatment and prevention that takes into account
individual variability in genes, environment, and lifestyle
for each person. Precision medicine is transforming clinical
and biomedical research, as well as health care itself from a
conceptual, as well as a methodological viewpoint, pro-
viding extraordinary opportunities to improve public health
and lower the costs of the healthcare system. However, the
implementation of precision medicine poses ethical–legal,
regulatory, organizational, and knowledge-related chal-
lenges. Without a national strategy, precision medicine,
which will be implemented one way or another, could take
place without the appropriate planning that can guarantee
technical quality, equal access of all citizens to the best
practices, violating the rights of patients and professionals,
and jeopardizing the solvency of the healthcare system.
With this paper from the Spanish Societies of Medical
Oncology, Pathology, and Hospital Pharmacy, we highlight
the need to institute a consensual national strategy for the
development of precision medicine in our country, review
the national and international context, comment on the
opportunities and challenges for implementing precision
medicine, and outline the objectives of a national strategy
on precision medicine in cancer.
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With this paper from the Spanish Societies of Medical
Oncology (SEOM), Pathology (SEAP), and Hospital
Pharmacy (SEFH), we propose to highlight the need to
institute a consensual national strategy for the development
of precision medicine in our country and promote its
implementation in the clinical practice with equity and
with assurances in terms of quality, efficiency, and legal
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guarantee, in addition to contributing to the sustainability
of the healthcare system.
Introduction
There is no universal definition for the term ‘‘precision
medicine’’, although probably, the most widely accepted is
the one provided by the US National Institutes of Health
(NIH) that defines it as ‘‘an emerging approach for disease
treatment and prevention that takes into account individual
variability in genes, environment, and lifestyle for each
person’’ [1]. Though at times used interchangeably with
personalized medicine, the National Research Council
prefers the term precision medicine instead, because per-
sonalized medicine might suggest that the different
strategies for treatment and prevention are developed
solely for each individual to the extent that ‘‘individual’’
refers to the specific individual and not in terms of
belonging to a particular biotype, as is truly the case with
precision medicine.
This definition gives rise to two fundamental conse-
quences. On the one hand, it entails a change of paradigm in
medicine in that the approach to disease is founded on the
genetic and molecular bases of health and disease to estimate
risks and inform decisions regarding prevention, diagnosis,
and treatment. Illnesses previously considered as a single
disease have now been disaggregated into several entities,
with different causal mechanisms that call for different
strategies. Inversely, diseases that were regarded as disparate
must be approached from the same point of view, given that
they have molecular mechanisms in common.
The concept of precision medicine necessarily involves
modifying the point at which health care commences,
understanding that patients’ treatment and needs depend
more on their particular characteristics than the generic
name of the disease. Likewise, knowing which nosological
groups a person is predisposed to as an individual will
make it possible to develop better prevention strategies.
Furthermore, individuals take a more active role in their
own health, by understanding their natural predisposition to
suffer certain diseases.
Precision medicine has already become a reality in daily
clinical practice in certain disciplines such as oncology; not
only is its implementation an ethical mandate and obliga-
tion of policy insofar as it represents an indisputable im-
provement in the treatment of patients and prevention of
disease, but it has also been proven to foster the sustain-
ability of the healthcare system in certain cases, by
selecting patients with a greater likelihood of response,
keeping patients from being exposed to expensive,
unnecessary treatments, while minimizing complications
derived from therapies with scant or no possibility of
response, and enables the most efficient preventive actions
to be selected for each individual.
International and national contexts and initiatives
By means of several national plans, the United States,
United Kingdom, France, Germany, China, and other
developed countries such as Finland and Estonia have
implemented national strategies endowed with state
funding to mobilize and strengthen the industry and
technological development associated with precision
medicine, channel the necessary private and public
resources to put them into effect, improve infrastructure,
and increase the current applications of this kind of
medicine.
Internationally, the International Consortium for Per-
sonalised Medicine (ICPerMed) constitutes the most rele-
vant project in Europe. It comprises the European
Commission and more than 30 European and extra-Euro-
pean partners and funding agencies [2]. Its main objective
is to stimulate research and the implementation of precision
medicine by means of meetings, workshops, conferences,
surveys, strategic publications, and joint initiatives. It ori-
gin lies in the preparatory workshops organized by the
European Commission, together with several subsequent
initiatives, including the seventh Framework Program and
the establishment of EuroBioForum and the consortium of
CASyM (http://www.casym.eu) in 2011 [3].
In France, for example, the Institut National du Cancer
(INCa) has an institutional framework to incorporate pre-
cision medicine into standard health care and the France
Médecine Génomique Plan 2025, published in 2016 and
with a projection until 2025, seeks to equip this country
with the means and industrial structure it needs to introduce
this new approach into health care and for this discipline to
be placed as a driver of economic development in France
[4]. Other countries, such as Estonia, Iceland, or the United
Kingdom, have developed initiatives to create population
biobanks that make it possible to establish associations
between biomarkers, clinical history, and lifestyle.
In the United States, the Precision Medicine Initiative,
announced by then President Obama, allocated 216 million
dollars in the 2016 fiscal year to fund a shared initiative of
the NIH, the National Cancer Institute (NCI), the Food and
Drug Administration (FDA), and the Office of the National
Coordinator for Health Information Technology (ONC).
The most distinctive aspect of this project is the creation of
a database in which one million volunteers will provide
genetic data, biological samples, and clinical information
with the aim of predicting risk, understanding how and why
common diseases occur and to improve diagnostic and
treatment strategies [5].
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To date, a general strategy on precision medicine has not
been developed at state level in Spain. Different National
Strategies compile recommendations for the development
of precision medicine (for instance, the National Health-
care System’s Strategies in Cancer and Rare Diseases). In
addition, there are national initiatives, such as the one put
forth by the National Institute of Health Carlos III [call for
projects in the field of precision medicine, participation in
the Network for Excellency for Research and Innovation
on Exosomes (REDIEX) or a European intergovernmental
organization for lifescience resources (ELIXIR), etc.],
together with local projects, such as the Comprehensive
Plan for Genomic Medicine in Catalonia, the Medical
Genome Project in Andalusia, the Future Clinic project in
the Valencian Region, or the MEDEA project in Extre-
madura [6].
Opportunities
Precision medicine is a reality in practical clinical health
care and has begun to shift the paradigms in medicine and
even change how diseases are classified. In general, pre-
cision medicine enhances effectiveness and efficiency,
since it makes it possible for the most appropriate strategies
to be used for each patient on the basis of the molecular
mechanism underlying the illness and the individual’s
genetic variability. Furthermore, it fosters the application
of the most suitable therapeutic scheme for patients, given
that it factors in the genetic variability determining drug
metabolism and pharmacodynamics, together with the
environmental factors that also play out in their disposition.
Thus, it prevents exposing patients to drugs that are not
useful for them, decreasing the possibilities of adverse
events related to drugs with no possibility of response, as
well as the secondary complications derived from treating
patients with ineffective drugs and the loss of opportunity
that this entails.
From an economic perspective, precision medicine is
regarded as an opportunity to develop an industrial sector
of high strategic, healthcare, scientific, and economic
value. The incorporation of our country at an early stage
would provide us with the chance to be technologically
independent in a sector that is more and more necessary,
and would also enable us to export knowledge and tech-
nology in a new industrial sector. All this represents an
unprecedented economic opportunity in our country that
would call for a hefty investment and mobilization of all
parties involved to achieve innovative technological solu-
tions (that include the fields of industry and information
technology) and a new form of economic development that
enables the device to be sustained beyond its start-up and to
respond to several technological challenges, in particular to
the development of the necessary information technology
capacities. Precision medicine is subject to international
competition and our country should not remain on the side
lines.
Finally, precision medicine is proposed as a tool to
contribute to rationalizing healthcare expenditure and to
the sustainability of the healthcare system; generating the
data needed to generalize initiatives that demonstrate cost
effectiveness.
Challenges
Ethical–legal and regulatory challenges
With the development of precision medicine, citizens and
healthcare systems confront new challenges, such as that of
maintaining the balance between risks and benefits, bearing
in mind the unprecedented ethical, economic, social, and
legal implications, in particular with respect to data
protection.
The identification of biomarkers and massive sequenc-
ing techniques is based on the collection and analysis of a
tremendous amount of information (‘‘big data’’). In this
context, it is imperative that the confidentiality of sensitive
personal data be guaranteed, especially in multicenter,
multinational projects that call for the shared use of data,
but also within the context of biobanks (despite the fact that
donors are generally anonymous, some biobanks require
that donors can be identified).
On the other hand, if samples are used for subsequent
research, doubts may arise as to who actually holds the
property rights over the samples, the validity of the consent
that was given, or about the right to the information (or to
non-information). This occurs to the degree to which genetic
testing makes it possible to identify or confirm the mutations
responsible for a disease that will probably develop in the
future or to identify a predisposition to developing it when
there are as yet no preventive techniques or effective treat-
ments available for many of those genetic diseases. Clear
regulations are, therefore, fundamental with the aim of
guaranteeing that the principle of universal and equal access
to healthcare be guaranteed. Furthermore, it is paramount
that the risk of citizens being excluded on the basis of their
genetic data and their predisposition to suffer certain dis-
eases be approached both legally and ethically.
The ethical dimension is an integral part of the imple-
mentation of an initiative of this nature. We must be able to
respond to the ethical and legal issues that arise from the
consent provided by citizens for the use of their health data
and to the complications derived from data anonymization,
the management of secondary discoveries and of untoward
incidents.
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Organizational and knowledge-related challenges
From a purely instrumental point of view, information
technology systems must be put into place to enable the
management and sharing of the vast amount of data gen-
erated by means of new generation sequencing techniques
[Big Data and Information and Communications Tech-
nologies (ITC) solutions]. The transformation to precision
medicine calls for new professional roles that are as yet not
included in healthcare systems, thus requiring the
involvement of professionals in the field of bioinformatics
and other professionals that currently participate under the
umbrella of research.
Moreover, clinical information and data from comple-
mentary testing are currently safeguarded by the healthcare
profession and/or by the institution that performed the
specific determinations; however, this model is not suit-
able for managing data coming from the next generation of
sequencing and that could have future medical applications
for individuals or for their descendants.
From a scientific perspective, precision medicine calls
for an even greater understanding of the molecular bases of
disease and of the interaction between genes and the
environment.
Furthermore, studies must be initiated to evaluate the
implementation of healthcare applications, which requires
substantial investment and a multidisciplinary approach.
Likewise, genetic, pharmacogenetic, and ‘‘omic’’ sci-
ences must be bolstered at the undergraduate and post-
graduate levels of training; promoting the continuous
education offer involving the leading scientific societies
and establishing the accreditation of reference centers.
Pharmacogenomics is one part of precision medicine, but it
must be complemented with pharmacology in order for this
new discipline to be created.
Even more important are the challenges associated with
the paucity of knowledge the general population has
regarding precision medicine. The acceptance of treatment
or prevention recommendations can be difficult, especially
bearing in mind that they deal with complex concepts and
that the dissemination of mistaken ideas about a kind of
genetic determinism without factoring in the modulating
effect of lifestyle and environment, could lead to a feeling
of defeatism and helplessness or, in contrast, could lead to
society’s becoming ‘‘medicalized’’, and instigate the per-
formance of unnecessary or dangerous testing, as well as to
potentially mistaken decisions about reproduction.
In this regard, the creation of a national platform is
decisive within the overall project for the incorporation of
precision medicine that can analyze and control the trans-
lation of scientific findings to clinical practice.
Finally, we must be mindful of the fact that in this
context, every new drug or technique can be developed for
a relatively small proportion of patients, making it neces-
sary for there to be other models to facilitate access to the
market from a regulatory perspective.
Objectives of a national strategy on precision
medicine
Taking into account the benefits, as well as the challenges
derived from this area of medicine, we set forth the fol-
lowing objectives of the different areas as being a priority:
Healthcare and quality objectives:
• To raise awareness among the population and decision
makers about the importance of precision medicine in
current medical and healthcare practice and its projec-
tions for the future.
• To incorporate precision medicine into the strategic
plans already in force and to prioritize it in national
health and research strategies, giving it the importance
that scientific evidence confers upon it in each case
uniformly throughout the territory.
• To facilitate access to precision medicine to all patients
with cancer and individuals with rare and common
diseases that are susceptible to it by creating sequencing
platforms that are capable of covering the whole country.
• To guarantee that the techniques used are accurate and
reliable, assuring the use of the best scientific evidence
available in basic and translational research.
• To facilitate the generation of information about health
outcomes.
• To develop the national legal framework to make the
regulation from the European Parliament and the
European Council regarding personal data protection
and the free circulation data feasible as well as to
develop those aspects left to national legislation.
Area of knowledge:
• To accelerate the design and execution of genetics-
based studies, exploring the basic aspects of tumor
biology and setting up a network of knowledge about
oncology that generates data and enables it to be shared
to stimulate information technology and scientific
discoveries and to inform clinical decisions.
• From a regulatory perspective, to promote the perfor-
mance of academic studies on response prediction by
means of biomarkers in those areas not covered by
industry.
• To foster the availability of comprehensive databases
that are validated and accessible and that include
genomic, biomedical, clinical, and lifestyle informa-
tion. To stimulate networking through corporate struc-
tures, enhancing the shared use and access to data
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regarding subpopulations, generated both within the
framework of clinical trials, as well as in real life.
• To organize technology that will make it possible to
analyze starting up a national center that enables the
genetic data generated to be processed and used and to
offer services for current applications.
• To develop training for healthcare professionals in the
application of precision medicine in healthcare
practice.
• To promote studies that analyze how pharmacoge-
nomics and pharmacokinetics relate to one another and
how they relate to measures of health outcomes.
• To stimulate university-level training in this new
branch of knowledge and to develop the new compe-
tences and technology needed to respond to the
challenge of using and interpreting data on a large
scale.
• To guarantee training of regulatory agents with the aim
of maintaining the necessary regulatory structure that
can guarantee innovation and make it possible to
protect public health.
• To promote citizens’ knowledge about health and
disease by encouraging the participation of volunteers.
Efficiency and sustainability:
• To put our country among the nations having the
capacity to develop and apply precision medicine and,
therefore, to export knowledge and technology.
• To develop the necessary regulatory frameworks to
guarantee a system to evaluate new drugs, biomarkers,
and efficient diagnostic methods.
• To foster a long-term economic model, capable of
integrating and developing the industrial fabric needed
to sustain the incorporation of precision medicine into
health on a large scale.
• To create an observatory that can monitor the evolution
of this field of medicine in its medical, technological,
ethical, and regulatory dimensions.
• To prepare the legal regulations and code of ethics that
make it possible to respond to the ethical and legal
demands associated with the collection, conservation,
and treatment of clinical and genomic data.
Conclusion
Precision medicine is transforming clinical and biomedical
research, as well as health care itself from a conceptual, as
well as a methodological viewpoint, providing
extraordinary opportunities to improve public health and
lower the costs of the healthcare system. Without a national
strategy, precision medicine, which will be implemented
one way or another, could take place without the appro-
priate planning that can guarantee technical quality, equal
access of all citizens to the best practices, violating the
rights of patients and professionals, and jeopardizing the
solvency of the healthcare system.
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